Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. Director Declaration

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Director Declaration

28 Oct 2025 07:05

RNS Number : 9938E
AstraZeneca PLC
28 October 2025
 

 

 

28 October 2025

 

Director Declaration

 

AstraZeneca PLC (the Company) today announced that Euan Ashley, Non-Executive Director of the Company, has been appointed a director of DexCom, Inc. with effect from 24 October 2025.

 

This announcement is made pursuant to Listing Rule 6.4.9 (2).

 

 

AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

 

Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Matthew BowdenCompany Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNQDLFLEBLZFBZ
12345678910
Date   Source Headline
22nd Dec 202511:00 amRNSDirector/PDMR Shareholding
22nd Dec 20257:30 amRNSEnhertu granted BTD for post-neoadjuvant early BC
22nd Dec 20257:30 amRNSEnhertu granted BTD for post-neoadjuvant early BC
22nd Dec 20257:00 amRNSUpdate on LATIFY Phase III trial of ceralasertib
22nd Dec 20257:00 amRNSUpdate on LATIFY Phase III trial of ceralasertib
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:05 amRNSSubcutaneous Saphnelo approved in EU
16th Dec 20257:00 amRNSEnhertu approved in US for 1L HER2+ metastatic BC
4th Dec 20253:00 pmRNSHolding(s) in Company
1st Dec 20253:05 pmRNSBlock listing Interim Review
1st Dec 20253:00 pmRNSTotal Voting Rights
26th Nov 20257:00 amRNSImfinzi approved in US for early gastric cancer
24th Nov 20257:00 amRNSAstraZeneca manufacturing investment in Maryland
20th Nov 20257:00 amRNSKoselugo (selumetinib) approved in the US
17th Nov 20253:00 pmRNSHolding(s) in Company
14th Nov 202511:00 amRNSDirector/PDMR Shareholding
10th Nov 20253:00 pmRNSDirector/PDMR Shareholding
6th Nov 20257:00 amRNS9M and Q3 2025 results
3rd Nov 20254:00 pmRNSResult of General Meeting
3rd Nov 20253:00 pmRNSTotal Voting Rights
28th Oct 20257:05 amRNSDirector Declaration
28th Oct 20257:00 amRNSKoselugo (selumetinib) approved in the EU
22nd Oct 20257:00 amRNSTezspire Approved in EU for CRSwNP
20th Oct 20257:05 amRNSUS FDA Approves Tezspire in CRSwNP
20th Oct 20257:00 amRNSPositive CHMP opinion for subcutaneous Saphnelo
13th Oct 20257:00 amRNSAgreement with US Govt to lower medicine prices
7th Oct 20257:00 amRNSBaxdrostat met primary endpoint in Bax24 Ph3 trial
6th Oct 20257:30 amRNSDatroway improved OS and PFS in TROPION-Breast02
1st Oct 20253:00 pmRNSTotal Voting Rights
29th Sep 20257:30 amRNSEnhertu improved IDFS in early BC in DB-05
29th Sep 20257:00 amRNSAZN harmonises listing structure
25th Sep 20254:30 pmRNSDirector/PDMR Shareholding
22nd Sep 20257:05 amRNSKoselugo recommended for EU approval
22nd Sep 20257:00 amRNSTezspire Recommended for Approval in EU for CRSwNP
17th Sep 20257:05 amRNSSaphnelo met primary endpoint in TULIP-SC
17th Sep 20257:00 amRNSUpdate on RESOLUTE Phase III trial
1st Sep 20253:00 pmRNSTotal Voting Rights
28th Aug 20253:00 pmRNSHolding(s) in Company
26th Aug 20253:00 pmRNSHolding(s) in Company
21st Aug 20253:00 pmRNSHolding(s) in Company
18th Aug 20253:00 pmRNSDirector/PDMR Shareholding
15th Aug 20253:00 pmRNSHolding(s) in Company
12th Aug 20253:00 pmRNSHolding(s) in Company
1st Aug 20253:00 pmRNSTotal Voting Rights
29th Jul 20257:00 amRNSH1 and Q2 2025 results
24th Jul 20257:00 amRNSGefurulimab nanobody met Phase III endpoints
22nd Jul 20257:00 amRNSAstraZeneca plans to invest $50bn in the US
16th Jul 20257:00 amRNSUpdate on anselamimab in AL amyloidosis
14th Jul 20257:00 amRNSBaxdrostat met primary endpt in BaxHTN PhIII trial
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
TMPL
Temple Bar Investment Trust
LSE
-1.01%
XTR
Xtract
LSE
13.64%
MTU
Montanaro Uk
LSE
0.46%
SHRS
Shires Inc.
LSE
0.00%
CKT
Checkit
LSE
0.00%
Trending
PPP
Pennpetro Energy
LSE
0.00%
ITM
Itm Power
LSE
-10.85%
GST
GSTechnologies
LSE
8.11%
NANO
Nanoco
LSE
-10.69%
LLOY
Lloyds
LSE
-1.33%